Genenta Science (NASDAQ:GNTA) Trading Down 0.8%

Genenta Science S.p.A. (NASDAQ:GNTAGet Rating) fell 0.8% on Thursday . The stock traded as low as $7.00 and last traded at $7.02. 476 shares were traded during trading, a decline of 95% from the average session volume of 9,053 shares. The stock had previously closed at $7.08.

The company’s fifty day moving average price is $6.87 and its two-hundred day moving average price is $7.57.

About Genenta Science (NASDAQ:GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.

Featured Articles

Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.